Alkem Laboratories Ltd
Alkem Laboratories Ltd Share Price Today: Live Updates & Key Insights
Get insights on Alkem Laboratories Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Alkem Laboratories Ltd Share Price Chart
Alkem Laboratories Ltd Fundamentals
Traded Volume: 4,77,859
Market Cap(Cr): 68,457
Avg Traded Price 3017.04
1 Year return 4.04%
Upper Circuit 5,868
Lower Circuit 5,679
P/E TTM 29.00
P/B Ratio 197.00
Traded Value(Cr) 27359.82
EPS TTM 197.466
Book value 197.466
Dividend 1.00%
Alkem Laboratories Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Alkem Laboratories Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Alkem Laboratories Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +1.45%
1M +4.24%
3M +11.20%
1Y +4.04%
YTD +3.53%
Alkem Laboratories Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Alkem Laboratories Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 1.73L
Day Before Yesterday 1.24L
1W Avg 1.73L
1M Avg 1.26L
3M Avg 1.61L
Alkem Laboratories Ltd Technical Details
Alkem Laboratories Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 5699
Support 2 5631
Support 3 5568
Pivot Point : 5762
Resistance 1 5830
Resistance 2 5893
Resistance 3 5961
Alkem Laboratories Ltd Corporate Actions
Alkem Laboratories Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Alkem Laboratories Ltd’s capital allocation strategies.
All
Ex-Date 08-Aug-2025 Type D Description 8.00/share@400.00% Record Date 08-Aug-2025 Ratio 400.00
Ex-Date 14-Feb-2025 Type D Description 37.00/share@1850.00% Record Date 14-Feb-2025 Ratio 1850.00
Ex-Date 09-Aug-2024 Type D Description 5.00/share@250.00% Record Date 10-Aug-2024 Ratio 250.00
Ex-Date 16-Feb-2024 Type D Description 35.00/share@1750.00% Record Date 17-Feb-2024 Ratio 1750.00
Ex-Date 10-Aug-2023 Type D Description 10.00/share@500.00% Record Date 10-Aug-2023 Ratio 500.00
Ex-Date 17-Feb-2023 Type D Description 25.00/share@1250.00% Record Date 18-Feb-2023 Ratio 1250.00
Ex-Date 17-Feb-2023 Type D Description 15.00/share@750.00% Record Date 18-Feb-2023 Ratio 750.00
Ex-Date 08-Aug-2022 Type D Description 4.00/share@200.00% Record Date 10-Aug-2022 Ratio 200.00
Ex-Date 10-Feb-2022 Type D Description 30.00/share@1500.00% Record Date 12-Feb-2022 Ratio 1500.00
Ex-Date 09-Aug-2021 Type D Description 5.00/share@250.00% Record Date 10-Aug-2021 Ratio 250.00
Ex-Date 11-Feb-2021 Type D Description 25.00/share@1250.00% Record Date 13-Feb-2021 Ratio 1250.00
Ex-Date 10-Aug-2020 Type D Description 3.00/share@150.00% Record Date 11-Aug-2020 Ratio 150.00
Ex-Date 13-Feb-2020 Type D Description 22.00/share@1100.00% Record Date 15-Feb-2020 Ratio 1100.00
Ex-Date 19-Aug-2019 Type D Description 8.00/share@400.00% Record Date 20-Aug-2019 Ratio 400.00
Ex-Date 15-Feb-2019 Type D Description 8.00/share@400.00% Record Date 18-Feb-2019 Ratio 400.00
Ex-Date 23-Aug-2018 Type D Description 7.00/share@350.00% Record Date 24-Aug-2018 Ratio 350.00
Ex-Date 16-Feb-2018 Type D Description 6.00/share@300.00% Record Date 20-Feb-2018 Ratio 300.00
Ex-Date 31-Aug-2017 Type D Description 9.00/share@450.00% Record Date 01-Sep-2017 Ratio 450.00
Ex-Date 23-Nov-2016 Type D Description 6.00/share@300.00% Record Date 24-Nov-2016 Ratio 300.00
Ex-Date 18-Mar-2016 Type D Description 9.70/share@485.00% Record Date 21-Mar-2016 Ratio 485.00
Dividends
Announcement Date 08-Aug-2025 Ex Dividend Date 08-Aug-2025 Dividend(%) 400
Announcement Date 14-Feb-2025 Ex Dividend Date 14-Feb-2025 Dividend(%) 1850
Announcement Date 09-Aug-2024 Ex Dividend Date 09-Aug-2024 Dividend(%) 250
Announcement Date 16-Feb-2024 Ex Dividend Date 16-Feb-2024 Dividend(%) 1750
Announcement Date 10-Aug-2023 Ex Dividend Date 10-Aug-2023 Dividend(%) 500
Announcement Date 17-Feb-2023 Ex Dividend Date 17-Feb-2023 Dividend(%) 1250
Announcement Date 17-Feb-2023 Ex Dividend Date 17-Feb-2023 Dividend(%) 750
Announcement Date 08-Aug-2022 Ex Dividend Date 08-Aug-2022 Dividend(%) 200
Announcement Date 10-Feb-2022 Ex Dividend Date 10-Feb-2022 Dividend(%) 1500
Announcement Date 09-Aug-2021 Ex Dividend Date 09-Aug-2021 Dividend(%) 250
Announcement Date 11-Feb-2021 Ex Dividend Date 11-Feb-2021 Dividend(%) 1250
Announcement Date 10-Aug-2020 Ex Dividend Date 10-Aug-2020 Dividend(%) 150
Announcement Date 13-Feb-2020 Ex Dividend Date 13-Feb-2020 Dividend(%) 1100
Announcement Date 19-Aug-2019 Ex Dividend Date 19-Aug-2019 Dividend(%) 400
Announcement Date 15-Feb-2019 Ex Dividend Date 15-Feb-2019 Dividend(%) 400
Announcement Date 23-Aug-2018 Ex Dividend Date 23-Aug-2018 Dividend(%) 350
Announcement Date 16-Feb-2018 Ex Dividend Date 16-Feb-2018 Dividend(%) 300
Announcement Date 31-Aug-2017 Ex Dividend Date 31-Aug-2017 Dividend(%) 450
Announcement Date 23-Nov-2016 Ex Dividend Date 23-Nov-2016 Dividend(%) 300
Announcement Date 18-Mar-2016 Ex Dividend Date 18-Mar-2016 Dividend(%) 485
Bonus
No Bonus has been declared by ALKEM
Splits
No Split has been declared by ALKEM
Others
Rights No Rights has been declared by ALKEM
Alkem Laboratories Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Alkem Laboratories Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Alkem Laboratories Ltd's relative performance and valuation against major competitors.
Stock Name Lupin Ltd ₹2052.90 (+0.93%) M. Cap (Cr) 937.69 1 Yr Return (%) -1.78% P/E (TTM) 21.68 PB Ratio 5.45
Stock Name Mankind Pharma Ltd ₹2257.00 (-0.57%) M. Cap (Cr) 931.60 1 Yr Return (%) -13.92% P/E (TTM) 53.21 PB Ratio 6.50
Stock Name Aurobindo Pharma Ltd ₹1210.20 (+2.25%) M. Cap (Cr) 709.10 1 Yr Return (%) -4.51% P/E (TTM) 20.54 PB Ratio 2.15
Stock Name Alkem Laboratories Ltd ₹5725.50 (-0.73%) M. Cap (Cr) 684.57 1 Yr Return (%) +4.04% P/E (TTM) 28.99 PB Ratio 5.71
Stock Name Abbott India Ltd ₹29570.00 (0.00%) M. Cap (Cr) 628.36 1 Yr Return (%) +3.40% P/E (TTM) 41.64 PB Ratio 14.84
Stock Name Glenmark Pharmaceuticals Ltd ₹1880.60 (+1.78%) M. Cap (Cr) 530.71 1 Yr Return (%) +19.25% P/E (TTM) 70.41 PB Ratio 6.00
Stock Name Laurus Labs Ltd ₹997.05 (+0.79%) M. Cap (Cr) 538.23 1 Yr Return (%) +103.67% P/E (TTM) 78.69 PB Ratio 12.03
Alkem Laboratories Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Alkem Laboratories Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 2189.41 Mar 2024 1686.56 Mar 2023 1437.42 Mar 2022 1299.34 Mar 2021 1324.48
PARTICULARS Investing Activities Mar 2025 -1007.41 Mar 2024 -865.60 Mar 2023 197.04 Mar 2022 -1669.33 Mar 2021 -1120.99
PARTICULARS Financing Activities Mar 2025 -1036.89 Mar 2024 -959.04 Mar 2023 -1711.27 Mar 2022 436.59 Mar 2021 -208.96
PARTICULARS Net Cash Flow Mar 2025 145.11 Mar 2024 -138.08 Mar 2023 -76.81 Mar 2022 66.60 Mar 2021 -5.47
Alkem Laboratories Ltd Shareholding Pattern
This shows the ownership breakdown of Alkem Laboratories Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 51.2%
Public 17.39%
Other Institutions 4.99%
FII 9.47%
Mutual Funds 16.94%
About Alkem Laboratories Ltd
Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. Alkem Laboratories Limited was incorporated as a private limited company on August 8, 1973 in Patna and subsequently became a deemed public limited company on October 26, 1988. Pursuant to Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to 'Alkem Laboratories Limited' with effect from October 26, 1988.In 1978, the company established its first plant at Taloja Maharashtra. In 1992, the company established its manufacturing facility in Mandwa, Maharashtra, which was later converted into an API facility in 2005. In 2003, the company set up a research and development facility for ANDA development at Taloja, Maharashtra.During the year 2006, the company's anti-infective drug Taxim became the first anti-infective drug in the Indian pharmaceutical industry to cross Rs 100 crore in terms of domestic sales in India. In 2007, the company filed its first ANDA in the US for the drug Amlodipine. In 2009, the company received first ANDA approval in US for Amlodipine. Also during the year, the company acquired Pharmacor Pty Ltd., a generic pharma company in Australia.In 2010, Alkem Laboratories acquired Ascend Laboratories, a generic marketing company in the US. In 2011, the company acquired Enzene, a company engaged in the development of biosimilars in India. In 2012, the company acquired an API manufacturing facility in the US.In 2014, the company acquired the 'Clindac-A' brand in India from Galderma S.A. Also during the year, Clavam crossed Rs 200 crore mark in terms of domestic sales in India. In 2015, the company acquired a formulation manufacturing facility in the US.During the FY2015,the company has done the stock split reduced the face value of equity share from Rs 10 to Rs 2 and also approved and allotted 59782500 bonus shares in the ratio of 1:1.On 23 December 2015, Alkem Laboratories successfully completed an Initial Public Offering (IPO) with its equity shares listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited.On 10 May 2016, Alkem Laboratories announced that the Competition Appellate Tribunal (COMPAT) has passed an order dated 10 May2016 setting aside the penalty of Rs 74.63 crore imposed on the company by the Competition Commission of India (CCI) in its order dated 1 December 2015.On 7 June 2016, Alkem Laboratories announced the closure of the inspection by the United Kingdom - The Medicines and Healthcare Products Regulatory Agency (UK-MHRA) for its Bioequivalence facility at Taloja, Maharashtra, India. The facility stands UK-MHRA compliant. On 11 August 2016, Alkem Laboratories announced that the USFDA inspected the company's Bioequivalence facility at Taloja, Maharashtra, India from 1 August to 10 August 2016. At the end of the inspection, there were no 483s issued by the USFDA. On 28 October 2016, Alkem Laboratories announced that the USFDA conducted a Bio-analytical inspection at the company's manufacturing facility located at Daman, India from 24 October to 28 October 2016. The inspection has been cleared successfully without any 483 observations. This inspection was based on an ANDA filed by the company.On 7 February 2017, Alkem Laboratories announced that it has entered into an alliance with Haw Par India Pvt Ltd., a wholly owned subsidiary of Haw Par Healthcare Ltd., Singapore to exclusively market, sell and distribute Tiger Balm range of products in India. Tiger Balm products will be promoted by Alkem Healthcare, an Over the Counter (OTC) division of Alkem. Tiger Balm range of products is an internationally known remedy for headaches, upper respiratory congestions, rheumatic or arthritic pains and muscular sprains. Its unique blend of herbal ingredients, derived from an ancient Chinese source, has been proven effective for nearly 100 years and is trusted by millions of people in more than 100 countries.On 29 March 2017, Alkem Laboratories announced that the USFDA has issued an Establishment Inspection Report (EIR) for its Ankaleshwar API facility which was inspected in December 2016. The inspection has now been closed by the USFDA. The USFDA had inspected the Ankaleshwar API manufacturing facility from 5 to 9 December 2016 and had issued Form 483 with three observations. Post this, the company had submitted a detailed corrective and preventive action plan (CAPA) to the regulator within the stipulated timelines. The USFDA has reviewed the CAPA and has found them acceptable. On 10 January 2018, Alkem Laboratories announced the closure of USFDA inspection at its Baddi facility in Himachal Pradesh.On 28 March 2018, Alkem Laboratories informed the stock exchanges that the USFDA conducted an inspection at the company's manufacturing facility located at Amaliya, Daman, India from 19 March 2018 to 27 March 2018. Post the inspection, the company has received a Form 483 with thirteen observations. The company said it will put together a detailed response with adequate corrective and preventive measures to address the USFDA observations within the timeline stipulated by the USFDA. The USFDA also conducted an inspection at the company's manufacturing facility located at St. Louis, USA from 12 March 2018 to 16 March 2018. In response to the one Form 483 observation issued by the USFDA, the company has submitted a detailed corrective and preventive action plan (CAPA) plan to the regulator within the stipulated timelines.During the FY2019, the wholly owned subsidiary of the Company Alkem Laboratories (NIG) Limited was dissolved w.e.f. 06th May, 2018 pursuant to voluntary winding up. As on 31 March 2019,the company had 20 subsidiary companies under its roof.In FY 2018-19, the company invested Rs 4.62 billion or 6.3% of total revenues in R&D, compared to 5.7% in FY 2017-18. The company filed 23 ANDAs during the year and received 21 approvals, which includes 6 tentative approvals. The company have a fairly strong product pipeline of 127 ANDAs (as on 31st March, 2019) already filed with the USFDA, with over half of them yet to be commercialised.The Company has also made investments in the biosimilar segment through its subsidiary Enzene Biosciences - a biotech-focussed company located in Pune (Maharashtra, India).The company bagged Express Pharma Excellence Award at Pharma CXO Summit 2019.During the FY2020, a new company named Ascend Laboratories SAS was incorporated on 04th June, 2019 as a wholly owned subsidiary of the Company in Colombia. Also on 08th April, 2020, a new company named S&B Pharma LLC had been incorporated as a Step down subsidiary of the Company in USA. As on 31 March 2020,the company had 21 subsidiary companies under its roof.During the year 2019-20, the company invested Rs 4,726 million or 5.7% of total revenues in R&D, as against Rs 4,622 million in FY 2018-19. The company filed 18 ANDAs during the year and received 22 ANDA approvals which includes 6 tentative approvals. Alkem now has a total of 144 ANDAs (as on 31st March, 2020) filed with the USFDA and 89 approvals.During the quarter ended 30 June 2020, the Company filed 4 abbreviated new drug applications (ANDAs) with the US FDA and received 2 approvals (including 1 tentative approval). As on June 30, 2020, the Company filed a total of 146 ANDAs and 2 new drug applications (NDA) with the USFDA. Of these, it has received approvals for 88 ANDAs (including 13 tentative approvals) and 2 NDAs.During the quarter ended 30 September 2020, the Company filed 1 abbreviated new drug applications (ANDAs) with the US FDA and received 4 approvals (including 1 tentative approval). As on September 30, 2020, the Company has filed a total of 147 ANDAs and 2 new drug applications (NDA) with the USFDA of which it has received approvals for 91 ANDAs (including 13 tentative approvals) and 2 NOA. During the quarter ended 31 December 2020, the Company received 10 approvals (including 2 tentative approvals) from the USFDA. As on December 31, 2020, the Company has filed a total of 147 ANDAs and 2 new drug application (NDA) with the US FDA of which it has received approvals for 100 ANDAs (including 14 tentative approvals) and 2 NOA.In FY'20, Company started new formulation manufacturing facility in Indore and a new biologic / biosimilar manufacturing facility in Pune. S&B Pharma LLC has been incorporated as a step down subsidiary of the Company in USA on 08th April, 2020, and on 12th June, 2020, the Company acquired M/s Connect 2 Clinic Private Limited, a Company incorporated under the Companies Act, 2013.For business synergies, ease of administration and simplification in the organization structure for its business operations in USA market, the Company's Board of Directors at its meeting held on 25 May 2021 has approved the proposed plan for restructuring of the USA business operations by bringing both the subsidiary entities namely, S & B Pharma Inc, USA (S & B) (engaged in manufacturing of pharmaceutical products and contract research) and The PharmaNetwork LLC, USA (TPNC) (engaged in sales & marketing of pharmaceuticals products) under a single umbrella by removing intermediary holding company S & B Holdings BV, Netherlands (S & B BV). This Board approved restructuring is subject to necessary statutory and regulatory approvals.During the quarter ended 31 March 2021, the Company filed 4 abbreviated new drug applications (ANDAs) with the US FDA and received 10 approvals (including 3 tentative approvals). During the FY2021,the Company filed 9 ANDAs with the US FDA and received 25 approvals (including 6 tentative approvals). As on March 31, 2021, the Company filed a total of 150 ANDAs and 2 new drug applications (NDA) with the US FDA. Of these, it has received approvals for 108 ANDAs (including 16 tentative approvals) and 2 NDAs.In FY'21, First product was launched from Enzene Biosciences in India. The Company ventured into respiratory segment in India with the launch of Pulmocare division. Connect2Clinic, the Company's online platform for participating medical professionals and healthcare staff to connect with theirpatients, witnessed a significant surge in activity. In FY'21-22, Connect2Clinic crossed an important milestone of 1 lakh doctor consultations and is growing fast to become a preferred end-to-end OPD management platform in India.During the year 2022-23, Enzene Inc., was incorporated as a step down subsidiary of the Company in USA on 26th May, 2022 and Pharmacor Limited, incorporated as a step down subsidiary of the Company in New Zealand on 01st June, 2022. The Company launched Adalimumab in the domestic markets in 2023. A new Marketing and Sales division, Metanext was launched in the Chronic segment.In 2023-24, Company launched world's first biosimilar of Cetuximab, namely Cetuxa. It ventured into the trade generics segment. Alkem Medtech Private Limited, got incorporated on March 27, 2024, in India, as a wholly owned subsidiary of the company.Global Capability Centre (GCC) was established for centralised enterprise operations in FY 2025.
Executive Chairman
Basudeo N Singh
Registered office Alkem House SenapatiBapat Marg, Lower Parel, Mumbai, Maharashtra, 400013
FAX :91-22-39829999
Background
Incorporation Year 1973
Face Value ₹2.00
Market Lot 1
FAQs on Alkem Laboratories Ltd
How to buy Alkem Laboratories Ltd shares on NSE?
To buy Alkem Laboratories Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Alkem Laboratories Ltd share price today?
The Alkem Laboratories Ltd share price on NSE is ₹5725.50 today.
What is the market cap of Alkem Laboratories Ltd on NSE?
The company has a market capitalization of ₹68456.94.
What is the PE & PB ratio of Alkem Laboratories Ltd?
PE is 29 and PB is 197.
What is the 52 Week High and Low of Alkem Laboratories Ltd shares?
Alkem Laboratories Ltd stock price high: ₹5868 Alkem Laboratories Ltd stock price low: ₹4491.65.
How can I purchase Alkem Laboratories stock?
You can conveniently buy Alkem Laboratories stock through a reputed brokerage like Motilal Oswal. You will have to open a demat account linked with a trading account and then you can purchase the stock through an exchange via Motilal Oswal.
Is Alkem overvalued?
Alkem Laboratories is one of the companies which is fairly valued at present. It stands in the category of companies which show positive trends in their quarterly results. Additionally, the company’s fundamentals may be considered average to good.
What is the dividend that Alkem declared?
The last dividend paid by Alkem Laboratories was on 17 February 2023, at Rs. 15 per share, which was an interim dividend. A special dividend was also paid on the same date, amounting to Rs. 25 per share.